Interestingly, Leone et al. have recently shown that treatment with JHU-083 increases the number of tumour-specific CD8+ T cells infiltrating the TME, these T cells are more proliferative, and appear to be robustly activated and less exhausted with improved effector functionality [58], in line with another finding that transient GLS-inhibition increases T-bet expression, skewing responses towards Th1 and increased cytotoxic T cell activity [41]. The gene discussed is CD8A; the disease is neoplasm.